Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Clinical Trial ID NCT01236573

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cancer statistics, 2007.	CA Cancer J Clin	2007	53.49
2	High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.	J Clin Oncol	1999	10.86
3	The basic principles of chimeric antigen receptor design.	Cancer Discov	2013	3.28
4	Chemotherapy for metastatic melanoma: time for a change?	Cancer	2007	1.99
5	IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.	J Clin Invest	2011	1.90
6	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
7	Trial Watch: Immunostimulatory cytokines.	Oncoimmunology	2012	1.19
8	Trial Watch: Adoptive cell transfer immunotherapy.	Oncoimmunology	2012	1.18
9	Interleukin 12: still a promising candidate for tumor immunotherapy?	Cancer Immunol Immunother	2014	1.17
10	Tumor evasion from T cell surveillance.	J Biomed Biotechnol	2011	1.01
11	Trial Watch: Adoptive cell transfer for anticancer immunotherapy.	Oncoimmunology	2014	0.96
12	Trial watch: Immunostimulatory cytokines in cancer therapy.	Oncoimmunology	2014	0.95
13	Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.	ISRN Oncol	2012	0.84
14	Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.	Hum Vaccin Immunother	2014	0.81